Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

* Bristol-Myers Squibb Co says under terms of agreement, Array and Bristol-Myers Squibb will jointly support study with Array acting as sponsor * Bristol-Myers Squibb Co - Collaboration to investigate ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...